Avadel Pharmaceuticals (AVDL) Return on Equity: 2009-2021
Historic Return on Equity for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to -0.71%.
- Avadel Pharmaceuticals' Return on Equity fell 112.00% to -1.00% in Q4 2021 from the same period last year, while for Dec 2021 it was -1.00%, marking a year-over-year decrease of 112.00%. This contributed to the annual value of -0.71% for FY2021, which is 62.00% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Return on Equity stood at -0.71% for FY2021, which was down 648.89% from -0.09% recorded in FY2020.
- Over the past 5 years, Avadel Pharmaceuticals' Return on Equity peaked at 5.76% during FY2019, and registered a low of -2.16% during FY2018.
- Its 3-year average for Return on Equity is 1.65%, with a median of -0.09% in 2020.
- Its Return on Equity has fluctuated over the past 5 years, first surged by 791bps in 2019, then tumbled by 585bps in 2020.
- Yearly analysis of 5 years shows Avadel Pharmaceuticals' Return on Equity stood at 1.07% in 2017, then slumped by 323bps to -2.16% in 2018, then surged by 791bps to 5.76% in 2019, then crashed by 585bps to -0.09% in 2020, then crashed by 62bps to -0.71% in 2021.